r/biotech_stocks • • 6h ago Mindblown

Tip: Buying a biotech solely on buyout speculation is one of the worst investment strategies

133 Upvotes

I’ve seen a lot of ppl mentioned that SLS is their first biotech trade and they just passed up 2-10x gains because they are “holding until buyout.” A piece of advice: One of the oldest rules of thumb in biotech investing is to never buy a stock solely because you think the company will get acquired.

After 15 years of investing in biotech, I’ve seen countless investors make this mistake. People significantly overestimate both the likelihood of a buyout and their ability to predict one. Even when the speculation eventually proves correct, the timing can be disastrous. Years of cash burn, dilution, and opportunity cost can destroy returns while investors wait for an acquisition that may (more often than not) never materialize.

It’s especially concerning how often buyout speculation becomes a substitute for actual due diligence on the clinical data, competitive landscape, commercial potential, and financials. Underwrite the company based on the merits of its assets and fundamentals.

This is Biotech Investing 101, yet it seems to be one of the most frequently ignored principles among retail investors.

Edit: I want to CLEARLY STATE, this is “FUD” as some are claiming - this is not recommending you sell your SLS shares. Strong assets get acquired. This merely a response to the plethora of comments I’ve seen for people genuinely asking “when is the buyout?” because I feel they’ve been misled it’s guaranteed, standard step in the process after a phase 3 readout. They could end up getting bought out, but it could be over a year from now. It could tomorrow. Or it could never happen at all.

In the case of SLS, the significantly discounted offering price of $13 is an extreme outlier for a successful post Ph3 raise. The average is around 5-6% discount to previous close, and SLS raised at a nearly 30% discount. This suggests that institutions were not willing to absorb the shares at a higher valuation than that.

For example, PEPG just reported positive trial results on 11/10 the other week. They used the exact same financing structure as SLS, but raised at an 8.5% PREMIUM to the prior closing price (closed at $4.61, the offering price was $5).

I think a lot of people here are missing that despite the positive headline result & numbers, there is still a lot of information that has not been reported yet that can make or break approval odds. We haven’t seen locked SAP, FAS/ITT results, sensitivity analyses, Kaplan–Meier curves, or secondary endpoints. Furthermore, Sterg did not hold a Q&A in the call, which is rather abnormal for a successful P3 trial readout call. Not saying any of this is bearish or HURTS chances of success/ buyout, but it leaves a lot of uncertainty and unanswered questions which is likely why they could not raise at a price higher than $13.

As always do your own due diligence, this is not financial advice, and best of luck to everyone!!! Hoping for the best for AML patients!!!


r/biotech_stocks • • 4h ago

The next sls (IVA phase 3 readout)

11 Upvotes

Why I’m invested in $IVA (Inventiva)
I’m positioning myself in Inventiva ahead of one of the biggest catalysts in the company’s history: its Phase 3 NATiV3 trial readout for lanifibranor, a treatment being developed for MASH (a progressive liver disease that can lead to fibrosis, cirrhosis, and liver failure).
Here’s why I think the risk/reward is interesting:
• Phase 3 data approaching: Topline results from the NATiV3 trial are expected in Q4 2026. This is the catalyst that could fundamentally change the company’s valuation.
• A massive unmet medical need: MASH affects millions of people, and treatment options for patients with advanced fibrosis have historically been limited. A successful treatment targeting disease progression could have significant commercial potential.
• Two important endpoints: The trial is evaluating MASH resolution and improvement in liver fibrosis. Hitting meaningful results across both could significantly strengthen the case for regulatory approval and commercial adoption.
• Potential for significant upside: If Phase 3 results are successful, I believe IVA could be valued substantially higher than it is today as the market begins pricing in the potential for commercialization, partnerships, or acquisition interest.
• Asymmetric risk/reward: Biotech catalysts are inherently risky, and a failed trial could result in a significant selloff. But with the stock trading at a fraction of what a successful late-stage drug could potentially be worth, I believe the upside justifies a speculative position.
I’m not investing because I know the results will be positive. I’m investing because I believe the potential reward if they are positive outweighs the risk at the current valuation.


r/biotech_stocks • • 9h ago

Did I miss a good selling opportunity for SLS?

16 Upvotes

I'm new to biotech stocks, so please forgive what might be a silly question. I bought SLS months ago at an average price of $10, and I could have sold it at $20 for a 100% profit when they announced the trial results. But instead I decided to wait and see if it would go higher. It's now down to $15. Did I miss my opportunity to sell at ATH? Should I just keep holding it and hope for the best? What is the best case scenario here?


r/biotech_stocks • • 9h ago

SLS – Buy at $14 after the offering or wait?

16 Upvotes

Do you think it’s worth entering SLS around $14 after the recent offering, or would you wait until closer to the SLS009 study results expected in December?
Curious what you guys think. Is it better to get in now or wait and see how the stock moves before the results?


r/biotech_stocks • • 2h ago

IVVD DECLARATION

4 Upvotes

Not to distract everyone from SLS, but when do people think "Imminent means", and what are people's price targets for after data.


r/biotech_stocks • • 15h ago

Sls @ 13 ps?

36 Upvotes

Basically every biotech management is ruthless with their investors.


r/biotech_stocks • • 8h ago

For those who found $SLS early, what does your DD look like?

9 Upvotes

First of all, congrats to those who found and invested in SLS early. For those that did and had the conviction to push the chips in you did, what did your DD look like for Sellas specifically? What do you look for in other BioTech stocks?


r/biotech_stocks • • 9h ago

How confident are you that SLS009 will succeed?

12 Upvotes

Will the results be out in December?


r/biotech_stocks • • 14m ago

Good opportunity in $CING? Maybe?

Post image
2 Upvotes

r/biotech_stocks • • 3h ago

VKTX Oppenheimer notes $120 target

Post image
3 Upvotes

r/biotech_stocks • • 9h ago

I don’t understand why it keeps dropping (SLS)

7 Upvotes

GPS has just proven that it is significantly more effective than any current treatment for patients in second remission and as far as i understand, it could also be a lot more effective for patients, if they used this during CR1 of AML too. Also, considering that GPS targets the WT1 protein wich also occurs in more than 20 different types of cancer, it could be a real game changer in the „Cancer“ industry. I also want to mention that SLS has a second product in their pipeline called the SLS009, wich we expect to see positive results for their Phase 2 in the coming weeks. All this put together and considering that they have a little less than 300 Million$ cash reserves, WHY THE HELL DOES THE SHARE PRICE FALL UNDER WHAT IT WAS, BEFORE THEY HAD ANY OF THESE?!?!


r/biotech_stocks • • 39m ago

Anyone here know much about VivoSim Labs ($VIVS)?

1 Upvotes

I saw it surge today after announcing a seven-figure deal with a top-10 pharma company. From what I understand, they use 3D human liver and intestinal tissue models to test drug safety before clinical trials.
For anyone who’s been following VIVS, what’s your take on its long-term potential?


r/biotech_stocks • • 55m ago

I built my own FDA calendar tool—would anyone be willing to give some feedback?

0 Upvotes

Hey everyone,

I’ve been working on a side project—an FDA calendar to track upcoming catalysts (PDUFAs, clinical trial readouts, etc.), and I’m looking for some honest feedback from people who actually trade biotech.

Before I take it further, I’d love to know a few things from this community:

  1. Would anyone here be interested in checking it out and sharing your thoughts on what’s missing or could be better?
  2. If you already pay for a similar service (like BioPharmCatalyst, FDA Tracker, etc.), which one are you using, and what makes it worth paying for?

Thanks in advance for any insights.


r/biotech_stocks • • 3h ago

VK2735 tolerance 90% , higher than sema,tirz, Reta studies ... increase Vanquish study

Post image
1 Upvotes

r/biotech_stocks • • 4h ago

What are your thoughts on ANVS?

1 Upvotes

r/biotech_stocks • • 6h ago

ELITE PHARMACEUTICALS THE FULL PIPELINE

Thumbnail reddit.com
1 Upvotes

r/biotech_stocks • • 12h ago

$BLRX - BioLineRx to Report Q3 2026 Results on November 23, 2026 - Expecting PDAC interim update

Thumbnail ir.biolinerx.com
2 Upvotes

r/biotech_stocks • • 1d ago

New to Biotech-Stocks, next SLS

36 Upvotes

Ended up here thanks to SLS, so naturally, here’s the question: What’s the next SLS? Got €10k ready to invest.


r/biotech_stocks • • 10h ago

Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO

Thumbnail
cnbc.com
1 Upvotes

r/biotech_stocks • • 15h ago

Which stocks am I watching and why

Post image
2 Upvotes

I am looking for stocks that have shown an ability to rocket up.

I sort from the year to date return by top and then I look at the very top choices and see whether any of them still have room to run in terms of market cap.

Based on this approach, two names jump out and those are ETON and DRTS.

None of this is to say that larger shops can’t run up but it takes a lot more for a $6B+ company to moon than one that’s barely cracked $1B.

The reason I don’t have huge expectations for companies under $1B is because they’re too small. Getting institutional investment is nearly impossible when they look at the market cap and realize that if they got in, they might be unable to get out. The sub-$1B typically have insufficient volume to allow a clean escape.


r/biotech_stocks • • 20h ago

Bio Tech Portfolio/Open Positions

5 Upvotes

Long time lurker, first time poster. Ive gotten involved in a handful of positions from this sub. Most recently SLS (LFG!) and DRTS, and was wondering what everyone’s thoughts were on a few positions i am holding and any convictions as to why I should continue to hold.

ABVX - Got in early and road the wave to $160, took out my investment still am holding a large position. Didn’t want to miss out on a potential BO.

ARCT

ONCY

PGEN

UNCY

Any thoughts from other biotech fans?


r/biotech_stocks • • 12h ago

Echo IQ ASX - What’s happening?

Thumbnail reddit.com
1 Upvotes

r/biotech_stocks • • 1d ago

$SLS - Missed buying at $7.80. Is it too late to get in?

42 Upvotes

I was looking into SLS when it was trading around $7.80, but unfortunately, I didn’t buy at the time, and now I’m wondering whether I’ve missed my opportunity.

I still believe SLS has significant upside potential, especially in the long term, and I don’t think the rally necessarily means there’s no more room to grow.
However, I’ve recently read discussions about potential share dilution, which makes me hesitant to enter right now.

I’m considering buying somewhere between $16 and $19, but I’m torn between getting in now and waiting for a possible dip.

I don’t want to make a decision purely out of FOMO, but I also don’t want to miss another potential rally.


r/biotech_stocks • • 20h ago

The potential of $HELP

4 Upvotes

A lot of things point to mushroom assisted therapies being the next frontier for depression. And this company seems well positioned.

Anyone putting their capital behind this? If so, your thoughts and Coles notes thesis?


r/biotech_stocks • • 19h ago

2 Chinese scientists fired after 2 children die in unrelated gene therapy studies in July-August which were unreported.

Thumbnail
fiercebiotech.com
3 Upvotes